Study Investigates Accuracy of Respiration Rate Obtained From Pulse Oximetry on Pediatric Patients Using Masimo RRp®
Masimo (NASDAQ: MASI) today announced the results of a study published in Pneumonia in which independent researchers in New Delhi, India, investigated the accuracy of Masimo RRp® on pediatric patients with the Rad-G™ Pulse Oximeter by comparing it to clinician-determined values while performing routine assessment of children admitted to outpatient and emergency departments.1 RRp provides respiration rate determined from the photoplethysmograph used in pulse oximetry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200705005031/en/
Masimo Rad-G™ with RRp® (Photo: Business Wire)
Noting the high incidence of childhood pneumonia in many parts of the world, the inclusion of oxygen saturation (SpO2) and respiratory rate measurement in pneumonia screening guidelines, and the scarcity of medical equipment and variability in medical training in many low-resource settings, Dr. Alwadhi and colleagues sought to determine whether a “multi-modal” pulse oximeter, Masimo Rad-G, could also accurately measure respiration rate—supporting future applications for a more streamlined and reliable approach to pneumonia screening case management. Rad-G uses a single Masimo SET® pulse oximetry sensor to measure both SpO2 and RRp, as well as pulse rate (PR), perfusion index (Pi), and pleth variability index (PVi®).
In this particular study, the researchers used Rad-G, alongside traditional pediatrician assessment, to measure the respiration rate of 97 children (aged 2 to 59 months) admitted to the outpatient and emergency departments at Kalawati Saran Hospital in New Delhi, over 2 weeks. They then analyzed the level of agreement between plethysmography-based respiration rate (RRp) and the clinicians’ assessment of respiration rate.
The researchers found that RRp and the control respiration rate measurement method showed “significant strong association (97%)” (p < 0.001), and that “values obtained either from pulse oximeter or by pediatrician (gold standard) are very close to each other.” For assessing fast breathing (defined as ≥ 50 breaths per minute (bpm) for infants 2 to 12 months and ≥ 40 bpm for children older than 12 months), RRp had high sensitivity (95%) and specificity (94%), with 95% accuracy. Based on these findings, the authors explained, “The sensitivity analysis, in addition, points to the reliability of the device in correctly identifying fast breathing, a major symptom of the disease [pneumonia], in 95% of the cases.” They also noted that Rad-G “allows for significantly integrated results of RR and SpO2 with high sensitivity and accuracy in health care settings, as well as the possibility of rapid detection.”
The researchers concluded, “There is a high degree of agreement between pleth-based RR using a [pulse oximetry device] and physician measured RR, indicating that the former provides reliable and accurate measurement. Current diagnosis and management of pneumonia in primary health care is based on variably trained health providers despite IMCI [Integrated Management for Childhood Illness] guidelines. The use of pulse oximeters, also recommended by the WHO, which can provide reliable measurement, would streamline pneumonia case management in these settings. The current study provides evidence of the reliability of pulse oximeter[s].”
Masimo RRp is CE marked and U.S. FDA 510(k) cleared. Rad-G is currently CE marked and the U.S. FDA 510(k) clearance is pending.
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.2 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,3 improve CCHD screening in newborns,4 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.5-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.9 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Iris® platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
* The use of the trademark Bridge is under license from Innovative Health Solutions
- Alwadhi V, Sarin E, Kumar P, Saboth P, Khera A, Gupta S, Kumar H. Measuring accuracy of plethysmography based respiratory rate measurement using pulse oximeter at a tertiary hospital in India. Pneumonia. 2020. 12:4. https://doi.org/10.1186/s41479-020-00067-2.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- Estimate: Masimo data on file.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo RRp® and Rad-G™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo RRp and Rad-G, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bentley Systems Announces Acquisition of SPIDA, Leader in Utility Pole Structure Management15.6.2021 01:05:00 EEST | Press release
Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the acquisition of SPIDA Software, developers of specialized software for the design, analysis, and management of utility pole systems. Founded in 2007 in Columbus, Ohio, SPIDA offers modeling, simulation, and data management software solutions to electric and communications utilities, and their engineering services providers, in the U.S. and Canada. The integration of SPIDA within Bentley’s OpenUtilities engineering software and grid digital twin cloud services will help address the challenges of transitioning to new renewable energy sources including for electric vehicle charging, of joint usage of utility poles to support broadband networks’ 5G expansion, and of modernizing and hardening the electric grid to maintain reliability and resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005811/en/ SPIDA
Piper Sandler Advises Heubach and SK Capital on Acquisition of Clariant Pigments14.6.2021 22:29:00 EEST | Press release
Piper Sandler & Co. chemicals & materials investment banking group (The Valence Group) announced today that it has advised The Heubach Group, in partnership with SK Capital Partners, on their acquisition of Clariant’s Pigments Business. The combined business will operate under the Heubach name, creating a global pigments leader generating over €900 million in annual sales. The transaction values Clariant Pigments at approximately CHF 805 million, with additional consideration of CHF 50 million contingent on the 2021 financial performance of the business unit. As part of the transaction, Clariant will be reinvesting for an ownership stake in the combined business, demonstrating its continuing commitment to the success of Clariant Pigments and the substantial growth opportunity in the combination with Heubach. Closing for the transaction is subject to customary conditions and approvals and is expected to take place in the first half of 2022. Headquartered in Langelsheim, Germany and with
SVPGlobal and EnTrust Global Complete Acquisition of DVB Bank’s Aviation Investment and Asset Management Business14.6.2021 22:13:00 EEST | Press release
The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced the completion of the acquisition of the Aviation Investment and Asset Management business from DVB Bank Group, resulting in the formation of Deucalion Aviation Limited (“Deucalion” or the “Company”). Deucalion is an innovative global platform with world class aviation expertise and the ability to invest across the capital spectrum to provide solutions to airlines and aviation investors. Led by Jon Skirrow and Stephan Sayre, with the support of EnTrust Global and SVPGlobal, Deucalion is a servicer for over 170 aircraft on lease to 86 airlines with clients including banks, investors, financiers and lessors. Jon Skirrow, Co-CEO & COO said: “This new investment creates a platform with collaboration at its heart to enable us to continue and expand
Esri’s Dr. Este Geraghty Receives HIMSS21 Most Influential Women in Health IT Award From HIMSS14.6.2021 19:10:00 EEST | Press release
HIMSS has announced Dr. Este Geraghty, the Chief Medical Officer for location intelligence world leader Esri, as a recipient of the Most Influential Women in Health IT Award. The award recognizes and celebrates influential women who harness the power of information and technology to transform health and healthcare. The winners are unique among power lists and award programs as it is inclusive of all women of influence, no matter where they may be in the health information and technology field. Dr. Este Geraghty, MD, MS, MPH, CPH, GISP, leads strategy and messaging for Esri’s Health and Human Services sector. Dr. Geraghty has been with the company since 2014 and has led business development and solution development in the market. During her time at Esri, Dr. Geraghty has helped organizations around the world use location intelligence to combat Zika virus, finish the fight against polio, grapple with the opioid crisis, combat homelessness, enhance health preparedness and response, inform
Verimatrix COO Asaf Ashkenazi To Present at Questex’s 2021 StreamTV Show14.6.2021 18:45:00 EEST | Press release
Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that COO Asaf Ashkenazi is slated to present a partner keynote session during the virtual StreamTV Show. The event is free and registration is available here. Scheduled to take place at 4 p.m. Eastern Time on Tuesday, June 15, Ashkenazi’s session is titled, “Security That Enables Amazing.” Aiming to educate viewers on the latest threats to streaming services, he will also outline the specific approaches to combating them while enabling new types of events and spawning new products. The keynote will introduce how to disrupt the pirates’ business model and dissuade them from their efforts in the first place. “While video consumption has evolved, so have piracy and other threats – making it more important than ever for streaming services to fight fire with fire,” Ashkenazi said. “We’re proud to serve as a diamond sponsor of this year’s StreamTV Show an
GE Aviation and Safran Launch Advanced Technology Demonstration Program for Sustainable Engines; Extend CFM Partnership to 205014.6.2021 17:33:00 EEST | Press release
GE Aviation and Safran today launched a bold technology development program targeting more than 20 percent lower fuel consumption and CO2 emissions compared to today’s engines. The CFM RISE (Revolutionary Innovation for Sustainable Engines) program will demonstrate and mature a range of new, disruptive technologies for future engines that could enter service by the mid-2030s. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210614005533/en/ John Slattery, President and CEO of GE Aviation and Olivier Andriès, CEO of Safran sign agreement extending the CFM International 50/50 partnership to the year 2050, declaring their intent to lead the way for more sustainable aviation in line with the industry’s commitment to halve CO2 emissions by 2050. (Photo: Business Wire) The companies today also signed an agreement extending the CFM International 50/50 partnership to the year 2050, declaring their intent to lead the way for more susta
Wipro Enables Zero Cost Transformation with Oracle Cloud Infrastructure14.6.2021 16:45:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced it is collaborating with Oracle to launch Wipro Zero Cost Transformation, a new offering that helps organizations migrate to the cloud. Wipro is a member of Oracle PartnerNetwork (OPN). As enterprises seek to generate value from the cloud, their journey is often hindered by excessive costs, ineffective implementations and slow processes. With Wipro’s Zero Cost Transformation, companies can migrate their workloads to Oracle Cloud Infrastructure (OCI) with lower cost, shift from a Capital expenditures (CapEx) to Operating expenses (OpEx) model, and benefit from application and infrastructure support provided under a managed-services framework. Zero Cost Transformation eliminates the challenge of dealing with multiple service providers for cloud migration and support. It also provides a seamless and risk-mitigated migration, as Wipr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom